The Effects of Oral Magnesium Supplementation on Glycemic Response among Type 2 Diabetes Patients

source extracted confidence: high 2026-04-09
#administration-oral #adult #blood-glucose #diabetes-mellitus-type-2 #dietary-supplements

The Effects of Oral Magnesium Supplementation on Glycemic Response among Type 2 Diabetes Patients

ELDerawi et al., 2018 | Nutrients | Rct

Citation

ELDerawi Wafaa A, Naser Ihab A, ... Abutair Ayman S. The Effects of Oral Magnesium Supplementation on Glycemic Response among Type 2 Diabetes Patients. Nutrients. 2018-Dec-26;11(1). doi:10.3390/nu11010044

Abstract

BACKGROUND: Magnesium (Mg) supplementation may help control glycemic response among type 2 diabetes (T2D) patients. OBJECTIVE: This study means to determine whether Mg supplementation improves glycemic control indicators in patients with T2D. METHODS: After one week of the dietary stabilization phase, 42 T2D patients were stratified according to sex, age, fasting blood sugar (FBS) and Mg levels and then randomly allocated into two groups. The intervention group was on 250 mg/day of elemental Mg for three months while the control group did not receive any type of supplements throughout the intervention period. RESULTS: The daily administration of 250 mg of elemental Mg indicated a significant improvement in HbA1C (8.32 to 7.96%, p < 0.001), insulin levels (IL) (15.56 to 12.18 μIU/mL, p < 0.001), C-peptide (2.28 to 1.90 ng/mL, p = 0.001), HOMA.IR (6.16 to 4.44, p < 0.001) and HOMA.β% (59.99 to 52.37, p = 0.036) of the intervention group when compared with the control group after three months of intervention. CONCLUSION: The results of this study revealed that oral Mg supplementation reduces insulin resistance and improves the glycemic control indicators among T2D patients. TRIAL REGISTRATION: current controlled trials PHRC/HC/32/15. Registered 5 October 2015.

Key Findings

The daily administration of 250 mg of elemental Mg indicated a significant improvement in HbA1C (8.32 to 7.96%, p < 0.001), insulin levels (IL) (15.56 to 12.18 μIU/mL, p < 0.001), C-peptide (2.28 to 1.90 ng/mL, p = 0.001), HOMA.IR (6.16 to 4.44, p < 0.001) and HOMA.β% (59.99 to 52.37, p = 0.036) of the intervention group when compared with the control group after three months of intervention.

Outcomes Measured

  • Requires manual extraction

Population

Field Value
Population t2d
Sample Size See abstract
Age Range See abstract
Condition diabetes

MeSH Terms

  • Administration, Oral
  • Adult
  • Blood Glucose
  • Diabetes Mellitus, Type 2
  • Dietary Supplements
  • Female
  • Humans
  • Insulin Resistance
  • Magnesium
  • Male
  • Middle Aged

Evidence Classification

  • Level: Rct
  • Publication Types: Journal Article, Randomized Controlled Trial
  • Vertical: magnesium-diabetes

Provenance

Source extracted via PubMed E-utilities API on 2026-04-09